Common TitleNEAT 022
Official Title Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)
Phase Phase IV
ClinicalTrials.gov NCT02098837
Treatments
Dolutegravir

Dolutegravir
Tradename:TivicayOther Names:DTGClass:Integrase Inhibitors (INSTI)Categories PharmacologySwitch/SimplificationAdverse Effects
Funding
Non-IndustrySt Stephens Aids Trust
References
- Gatell JM, Assoumou L, Moyle G, et al. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS. 2017;31:2503-14.